diagnostic procedures further decrease the natural resistance to infection. Finally, granulocytopenia compromises the first line of defense against bacterial, fungal and paraType, severity and incidence of infection during the neutropenic period after peripheral blood stem cell transsitic pathogens. Fever of unknown origin, bacteremia and pneumonia are the most frequent clinical manifestations of plantation (PBSCT) for treatment of malignant disease were studied in 66 patients treated at a single instiinfection in patients after chemotherapy. 3 Infections with both gram-positive and gram-negative bacteria as well as tution. Data of 34 female and 32 male patients with a median age of 43 years suffering from leukemia (12), fungi are common in these patients. In particular, staphylococci, streptococci, E.coli, klebsiella, pseudomonas, canlymphoma (35), multiple myeloma (six) or solid tumors (13) were retrospectively analyzed. All patients had dida and aspergillus species are frequently isolated from infectious sites in granulocytopenic patients. received at least 2.5 ؋ 10 6 CD34-positive cells for stem cell rescue after high-dose chemotherapy. Ninety-four
blood stem cells during this period. The clinical characterat least once daily in case of elevated body temperature Ͼ38.0°C. The diagnosis of a documented bacterial infecistics of the study patients are summarized in Table 1 . Thirty-four female and 32 male patients suffered from acute tion was based on the occurrence of at least one positive culture in the face of appropriate clinical findings. All myelogenous leukemia (AML), chronic myelogenous leukemia (CML), non-Hodgkin's lymphoma, Hodgkin's dismedication was applied through central venous catheters throughout the in-patient period. Platelet transfusions were ease, acute lymphoblastic leukemia (ALL), breast cancer, mutliple myeloma and testicular cancer. Only patients with administered in the case of thrombocytopenia less than 10/nl in asymptomatic patients, Ͻ20/nl in febrile patients an age of less than 60 years and preserved function of all vital organs were treated with high-dose chemotherapy or in the case of hemorrhagic diathesis being present. Leukocyte-depleted erythrocyte concentrates were given to and PBSCT.
All patients had received chemotherapy for mobilization patients with a hemoglobin concentration Ͻ8 g/dl.
In febrile patients a thorough physical examination and of stem cells. Fifty-six patients received G-CSF at a dose of 5-10 g/kg, nine patients received sequential treatment chest X-ray were performed. All patients received i.v. antibiotics after one measurement of an elevated body temperawith interleukin-3 5 g/kg plus G-CSF 10 g/kg for mobilization of stem cells. Peripheral blood stem cells were ture Ͼ38.3°C or two times body temperature Ͼ38.0°C. Empiric antibiotic therapy was performed according to preobtained by repeated leukaphereses. Leukaphereses were started after a rise of leukocytes to above 0.8/nl and more viously published guidelines. 19 In 58 patients, antimicrobial treatment was started with a triple combination with ␤-than 0.5% CD34-positive cells in the peripheral blood and were repeated until a minimum number of 2.5 ϫ 10 6 CD34-lactam, aminoglycoside and glycopeptide. One patient received a ␤-lactam with aminoglycoside, three patients positive cells/kg was harvested. Different conditioning regimens were applied according to diagnosis and disease were started with ␤-lactam monotherapy. Antibiotic treatment was continued until disappearance of all clinical status (Table 1) . Peripheral stem cells were infused intravenously 1-3 days after discontinuation of chemotherapy.
and/or microbiological evidence for infection and granulocyte counts above 0.5/nl. In case of persistent fever, i.v. During PBSCT procedure patients were kept in single rooms under reverse isolation. Rooms were not equipped amphotericin B was added 2-5 days after start of antibiotic treatment. Modifications of the antibiotic regimen were perwith high-efficiency air filters. All patients received antibiotic prophylaxis with ofloxacin 2 ϫ 200 mg per day and formed, if appropriate, according to microbiologic results. Thirty-seven patients received 5 g G-CSF s.c. beginning antimycotic prophylaxis with fluconazole 2 ϫ 200 mg per day. Appropriate clinical examinations were performed day 2 after peripheral stem cell transplantation, whereas the remaining patients were not treated with recombinant once daily and body temperature was measured at least three times daily. Routine cultures from stool, urine and growth factors during the post-transplant period. No differences regarding leukocyte recovery, thrombocyte recovery mouth swabs were examined twice weekly for contaminating pathogens. In addition, two blood cultures were drawn and incidence of infection were observed between these two patient groups. All data were analyzed with descriptive statistical as fever of unknown origin. The response to antimicrobial therapy was prompt in the majority of patients. Forty-three out of 62 febrile patients the post-chemotherapy period ( Table 2 ). The thrombocyte defervesced within 5 days after the start of empiric anticounts recovered with a similar kinetics as leukocyte biotic treatment. Accordingly, only 18 out of 62 patients counts. In 90% of the patients the thrombocyte counts recorequired empirical treatment with intravenous amphotericin vered to Ͼ50/nl within 20 days. The remaining patients all B. Sytemic fungal infections were not observed in these recovered to safe thrombocyte levels within 26 days. Sixtypatients. Neither proven nor probable fungal infections two out of 66 patients required substitution of erythrocyte were diagnosed in the 66 patients. concentrates.
Only minor differences in type, frequency and duration of infection were observed in patients with different underlying diseases (Table 4) 
. Most of the patients became Type and incidence of infection in patients treated with
febrile during the neutropenic episode. The onset of fever high-dose chemotherapy and peripheral blood stem cell was rapid in all disease groups within a few days after the transplantation onset of leukopenia. The pattern of clinically documented Sixty-two out of 66 (94%) of patients experienced at least infection was also not different. Pneumonia was rare in all one febrile episode during the neutropenic phase subpatients irrespective of the diagnosis. The incidence of bacsequent to peripheral stem cell transplantation (Table 3) . teremia was slightly decreased in patients with malignant A median time to defervescence of 4 days was observed. lymphoma compared to the other patient groups. This difMicrobiologically and/or clinically documented infection ference, however, did not reach statistical significance. occurred in 32 patients (48%). Bacteremia was the preSimilarly, the response of all patient groups as measured dominant type of infection in this patient group and was by the median time to defervescence to antimicrobial therdocumented in 26 out of 66 patients (39%). Gram-positive apy was similar. pathogens, mostly coagulase-negative staphylococci, were the most frequent cause of bacteremia and were recovered from blood culture in 23 patients (34%). In five patients Discussion streptoccoci (Viridance strep. in two, Strep. mitis in two,
Infections were observed at a very high frequency in patients treated with intensive chemotherapy and peripheral Bacteremia was detected in 39% of the patients and was more common after PBSCT than in patients with aggressive chemotherapy for treatment of solid tumors or acute leukemarrow transplant recipients. 15, 16 It can be concluded that appropriate antimicrobial therapy protects the PBSCT mias. Large studies in those patient groups revealed an incidence of bacteremia in the range of 10-30%.
3,20-22 Simipatients from development of severe organ infection for a limited time period irrespective of the severity of the prelarly, bacteremia was observed in 84 out of 396 chemotherapy cycles (21%) in acute myeloid leukemia ceding neutropenia. This analysis of incidence and severity of infection in an unselected series of patients treated with patients treated at our institution during the same time period and according to the same guidelines as the study high-dose chemotherapy and PBSCT further confirms that peripheral blood stem cells are an effective measure for patients (unpublished data). The pathogens responsible for bacteremia in PBSCT patients were gram-positive bacteria prevention of severe infections associated with prolonged aplasia. However, the empirical anti-infective therapy in 88% of cases, whereas highly pathogenic gram-negative bacteria were rarely cultured. Several mechanisms might should be modified according to the specificities of the neutropenic period after PCSCT. In particular, start of empiriexplain this high incidence of gram-positive bacteremia after PBSCT. Central venous lines have been reported to cal treatment with a combination including a glycopeptide antibiotic or delay of the start of empirical amphotericin B be the most common site of entry for gram-positive pathogens. 23 However, intravenous devices are part of the stantreatment seems rational in view of the epidemiology of infection in PBSCT patients. Such interventions should be dard care both in acute leukemia and PBSCT patients. Thus it seems unlikely that use of the same type of catheter durfurther explored in randomized clinical trials. ing a neutropenic episode of comparable duration causes highly different rates of gram-positive infection. High-dose chemotherapy, however, almost invariably leads to severe Acknowledgements mucositis during the neutropenic phase. The gram-positive bacteria identified in blood cultures in the PBSCT patients individuals. 24 Thus, severe mucosal damage might be at least in part responsible for the high frequency of grampositive bacteremia in PBSCT patients. However, the References present data do not prove this hypothesis.
In contrast to the high incidence of gram-positive bacter- episodes in PBSCT patients are severe, but of shorter dur-
